Morgan Stanley
HRMY icon

Morgan Stanley’s Harmony Biosciences HRMY Stock Holding History

Morgan Stanley’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7M Sell
733,684
-297,334
-29% -$9.38M ﹤0.01% 2828
2026
Q1 		$28.9M Buy
1,031,018
+213,511
+26% +$7M ﹤0.01% 2614
2025
Q4 		$30.6M Sell
817,507
-30,388
-4% -$999K ﹤0.01% 2549
2025
Q3 		$23.4M Buy
847,895
+89,032
+12% +$3.07M ﹤0.01% 2744
2025
Q2 		$24M Buy
758,863
+102,759
+16% +$3.31M ﹤0.01% 2618
2025
Q1 		$21.8M Sell
656,104
-150,779
-19% -$5.41M ﹤0.01% 2606
2024
Q4 		$27.8M Sell
806,883
-43,795
-5% -$1.5M ﹤0.01% 2426
2024
Q3 		$34M Buy
850,678
+14,567
+2% +$512K ﹤0.01% 2237
2024
Q2 		$25.2M Sell
836,111
-49,234
-6% -$1.48M ﹤0.01% 2411
2024
Q1 		$29.7M Sell
885,345
-200,870
-18% -$6.45M ﹤0.01% 2255
2023
Q4 		$35.1M Buy
1,086,215
+330,770
+44% +$9.23M ﹤0.01% 2085
2023
Q3 		$24.8M Buy
755,445
+25,421
+3% +$883K ﹤0.01% 2231
2023
Q2 		$25.7M Buy
730,024
+167,952
+30% +$5.8M ﹤0.01% 2211
2023
Q1 		$18.4M Buy
562,072
+165,756
+42% +$7.55M ﹤0.01% 2523
2022
Q4 		$21.8M Buy
396,316
+73,534
+23% +$4.04M ﹤0.01% 2252
2022
Q3 		$14.3M Buy
322,782
+109,305
+51% +$5.33M ﹤0.01% 2577
2022
Q2 		$10.4M Buy
213,477
+51,903
+32% +$2.34M ﹤0.01% 3028
2022
Q1 		$7.86M Sell
161,574
-9,533
-6% -$389K ﹤0.01% 3189
2021
Q4 		$7.3M Buy
171,107
+126,623
+285% +$5.05M ﹤0.01% 3315
2021
Q3 		$1.71M Sell
44,484
-84,272
-65% -$2.71M ﹤0.01% 4693
2021
Q2 		$3.63M Buy
128,756
+64,929
+102% +$1.95M ﹤0.01% 4115
2021
Q1 		$2.11M Buy
63,827
+42,961
+206% +$1.51M ﹤0.01% 4219
2020
Q4 		$755K Buy
20,866
+20,816
+41,632% +$840K ﹤0.01% 4820
2020
Q3 		$2K Buy
+50
New +$1.82K ﹤0.01% 6571

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's HRMY Position: Q2 2026 in Review

Morgan Stanley reduced its Harmony Biosciences (HRMY) stake by 29% in Q2 2026, selling an estimated $9.38M and leaving 733,684 shares worth $26.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2828.

Morgan Stanley first reported a position in HRMY in Q3 2020 and has held it in 24 quarters since. The position peaked at $35.1M in Q4 2023. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Morgan Stanley held 733,684 shares of Harmony Biosciences worth $26.7M as of Q2 2026.
  • Morgan Stanley sold 297,334 Harmony Biosciences shares in Q2 2026, an estimated $9.38M.
  • Harmony Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2828 holding.
  • Morgan Stanley first reported a position in Harmony Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's Harmony Biosciences position peaked at $35.1M in Q4 2023.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.